Vimarsana
Biggest News Aggregation in the World

Page 5 - Laboratory Abnormalities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Laboratory Abnormalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Laboratory Abnormalities Today - Breaking & Trending Today

Aadi Bioscience Announces Exploratory Biomarker Data from - Vimarsana News

Aadi Bioscience Announces Exploratory Biomarker Data from

Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor...

UPDATE -- Aadi Bioscience Reports First Quarter 2022 - Vimarsana News

UPDATE -- Aadi Bioscience Reports First Quarter 2022

FYARRO net product sales of $2.3 million in partial first quarterDosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic...

Frontiers | The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection - Vimarsana News

Frontiers | The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has been drastically affecting the daily lives of millions of people. COVID-19 is described as a multiorgan disease that affects not only the respiratory tract of infected individuals, but it has considerable effects on the musculoskeletal system, causing excessive fatigue, myalgia, arthralgia, muscle weakness and skeletal muscle damage. These symptoms can persist for months, decreasing the quality of life of numerous individuals. Curiously, most studies in the scientific literature focus on patients who were hospitalized due to S...

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Vimarsana News

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®...

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Vimarsana News

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence dat...